1. Home
  2. TKLF vs ALZN Comparison

TKLF vs ALZN Comparison

Compare TKLF & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TKLF

Yoshitsu Co. Ltd

N/A

Current Price

$1.63

Market Cap

8.3M

ML Signal

N/A

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

N/A

Current Price

$1.73

Market Cap

7.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKLF
ALZN
Founded
2006
2016
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
TKLF
ALZN
Price
$1.63
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $28.00
AVG Volume (30 Days)
6.5K
★ 99.5K
Earning Date
12-19-2025
03-11-2026
Dividend Yield
★ 10.97%
N/A
EPS Growth
N/A
★ 76.77
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.84
52 Week High
$3.92
$2.68

Technical Indicators

Market Signals
Indicator
TKLF
ALZN
Relative Strength Index (RSI) 39.82 62.26
Support Level N/A $1.69
Resistance Level $2.43 $2.22
Average True Range (ATR) 0.11 0.09
MACD 0.00 -0.01
Stochastic Oscillator 14.12 70.61

Price Performance

Historical Comparison
TKLF
ALZN

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Share on Social Networks: